Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study

The Lancet Haematology

Volumn 4, Issue 11, 2017, Pages e553-e561

  Allen, Elizabeth S ^a   Srivastava, Kshitij ^a   Hsieh, Matthew M ^b   Fitzhugh, Courtney D ^b   Klein, Harvey G ^a   Tisdale, John F ^b   Flegel, Willy A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; ERYTHROCYTE ANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL OUTCOME; DEATH; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SC DISEASE; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTOPENIA; RISK ASSESSMENT; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TRANSPLANTATION CONDITIONING;

ADULT; ANEMIA, SICKLE CELL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 85042152831     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(17)30196-5     Document Type: Article

References (30)

1. Johnson, FL, Look, AT, Gockerman, J, Ruggiero, MR, Dalla-Pozza, L, Billings, FT 3rd, Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 311 (1984), 780–783.
2. Vermylen, C, Cornu, G, Ferster, A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 22 (1998), 1–6.
3. Walters, MC, Patience, M, Leisenring, W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7 (2001), 665–673.
4. van Besien, K, Bartholomew, A, Stock, W, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 26 (2000), 445–449.
5. Iannone, R, Casella, JF, Fuchs, EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 9 (2003), 519–528.
6. Horan, JT, Liesveld, JL, Fenton, P, Blumberg, N, Walters, MC, Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 35 (2005), 171–177.
7. Horwitz, ME, Spasojevic, I, Morris, A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant 13 (2007), 1422–1426.
8. Krishnamurti, L, Kharbanda, S, Biernacki, MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 14 (2008), 1270–1278.
9. Hsieh, MM, Kang, EM, Fitzhugh, CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361 (2009), 2309–2317.
10. Matthes-Martin, S, Lawitschka, A, Fritsch, G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol 90 (2013), 308–312.
11. Bhatia, M, Jin, Z, Baker, C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 49 (2014), 913–920.
12. Hsieh, MM, Fitzhugh, CD, Weitzel, RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 312 (2014), 48–56.
13. Saraf, SL, Oh, AL, Patel, PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant 22 (2016), 441–448.
14. Shenoy, S, Eapen, M, Panepinto, JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 128 (2016), 2561–2567.
15. Hsieh, MM, Fitzhugh, CD, Tisdale, JF, Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 118 (2011), 1197–1207.
16. Griffith, LM, McCoy, JP Jr, Bolan, CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 128 (2005), 668–675.
17. Bolan, CD, Leitman, SF, Griffith, LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 98 (2001), 1687–1694.
18. Canals, C, Muniz-Diaz, E, Martinez, C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion 44 (2004), 1603–1611.
19. Worel, N, Kalhs, P, Keil, F, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 43 (2003), 1153–1161.
20. Franchini, M, Gandini, G, Aprili, G, Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 33 (2004), 1169–1172.
21. Senzel, L, Boulad, F, Wuest, D, Reid, ME, Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization. Transfusion 47 (2007), 781–787.
22. Cid, J, Lozano, M, Klein, HG, Flegel, WA, Matching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes. Blood Transfus 12 (2014), 301–306.
23. Klein, HG, Anstee, DJ, Mollison's blood transfusion in clinical medicine, 12th edn., 2014, Wiley-Blackwell, Hoboken, NJ.
24. McPherson, ME, Anderson, AR, Haight, AE, et al. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor. Transfusion 49 (2009), 1977–1986.
25. Fitzhugh, CD, Hsieh, MM, Taylor, T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv 1 (2017), 652–661.
26. Fasano, RM, Monaco, A, Meier, ER, et al. RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management. Blood 116 (2010), 2836–2838.
27. Chou, ST, Jackson, T, Vege, S, Smith-Whitley, K, Friedman, DF, Westhoff, CM, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 122 (2013), 1062–1071.
28. Flegel, WA, Gottschall, JL, Denomme, GA, Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematol 2 (2015), e282–e288.
29. King, AA, Kamani, N, Bunin, N, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol 90 (2015), 1093–1098.
30. Tatari-Calderone, Z, Gordish-Dressman, H, Fasano, R, et al. Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease. Hum Immunol 77 (2016), 35–40.